Scilex Holding Co Stock Price, News & Analysis

Scilex Holding Company (Nasdaq: SCLX) announced that the SEC has declared effective the Form S-4 registration statement for the proposed business combination between Denali Capital Acquisition Corp. (OTCB: DNQAF) and Semnur Pharmaceuticals, Scilex's majority-owned subsidiary.

The extraordinary general meeting for Denali shareholders is scheduled for September 3, 2025, at 9:00 AM ET in New York. Shareholders of record as of August 12, 2025, will be eligible to vote. Upon completion, the combined company will be renamed to Semnur Pharmaceuticals, Inc. While an application for Nasdaq listing has been submitted, approval remains pending.

Scilex Holding Company (Nasdaq: SCLX), a company focused on non-opioid pain management products, has announced the deferral of its previously announced dividend record date. The dividend, which consists of Scilex preferred stock exchangeable for up to 10% of Scilex's ownership interest in Semnur Pharmaceuticals, was originally scheduled for May 2, 2025.

The Board of Directors will determine a new record date at their discretion and maintains the right to further modify the date or revoke the dividend entirely. This dividend would affect both stockholders and certain other securityholders of Scilex.

Scilex Holding Company (SCLX) announced a publication highlighting GLOPERBA's dosing adjustments in a peer-reviewed journal. GLOPERBA is the first liquid oral colchicine for gout flare prophylaxis, enabling precision dosing for patients with renal impairment. The study reveals that patients with renal issues taking standard colchicine formulations often receive sub-optimal or excessive doses. The research demonstrates that GLOPERBA's liquid format allows for more precise dosing: 0.48 mg for moderate renal impairment and 0.3 mg for severe renal impairment, leading to better therapeutic outcomes. This is particularly significant as over 70% of gout patients have comorbid conditions requiring dose adjustments.

Scilex Holding Company (NASDAQ: SCLX) presented a post-hoc analysis of their C.L.E.A.R. trial at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP). The analysis focused on interpreting the clinical meaningfulness of SP-102 (SEMDEXA™) for treating lumbosacral radicular pain (LRP).

The results demonstrated that SP-102 showed clinically meaningful separation from placebo across multiple endpoints, including NPRS Responder Analyses, ODI, and BPI Pain Interference. The effectiveness was particularly notable in the modified intent-to-treat (mITT) population. When compared to other marketed analgesics for chronic low back pain and TSIs, SP-102's standard effect size showed promising results.

The drug was specifically formulated to provide a safer alternative to current off-label products that carry warnings of potentially dangerous and life-threatening adverse events. The overall benefit-risk profile suggests SP-102 could be a safe and effective treatment option for LRP patients.

Scilex Holding Company (NASDAQ: SCLX) announced it will present a post-hoc analysis of their C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) from May 15-17, 2025 in Orlando, FL. The presentation will focus on interpreting the clinical meaningfulness of safety and efficacy data for SP-102 (SEMDEXA™) in treating lumbosacral radicular pain (LRP).

The poster presentation will be displayed throughout the meeting and will be accessible via the conference app. Additionally, it will be published in the Pain Physician journal. The research was conducted by a team of authors including Miller AM, Knezevic NN, Nalamachu S, and others.

Scilex Holding Company has successfully regained compliance with Nasdaq's minimum bid price requirement. The company, trading under the symbol SCLX, met the crucial requirement of maintaining a minimum closing bid price of $1.00 per share for at least ten consecutive trading days, achieving this milestone on April 30, 2025.

As a result, Scilex will continue trading on the Nasdaq Capital Market under the symbols "SCLX" for common stock and "SCLXW" for public warrants. The company specializes in non-opioid pain management products, focusing on treatments for acute and chronic pain, along with neurodegenerative and cardiometabolic diseases.

This compliance achievement ensures Scilex maintains its position on the Nasdaq exchange, providing stability for this revenue-generating pharmaceutical company that develops and commercializes innovative pain management solutions.

Scilex Holding Company (SCLX) has announced a change in the record date for its previously declared dividend of preferred stock. The dividend, which is exchangeable for up to 10% of Scilex's ownership interest in its wholly owned subsidiary Semnur Pharmaceuticals, will now have a record date of May 2, 2025, instead of the previously announced April 11, 2025.

The payment date will be determined by subsequent Board resolutions and will occur within 60 days following the new record date. Scilex, which focuses on non-opioid pain management products for acute and chronic pain, neurodegenerative and cardiometabolic disease treatments, maintains its commitment to delivering value to its stockholders and securityholders through this dividend distribution.

Scilex Holding Company (NASDAQ: SCLX) has received FDA approval for Orphan Drug Designation for colchicine in treating pericarditis. Their product Gloperba®, the first and only liquid oral colchicine, is currently indicated for gout flare prophylaxis in adults.

Gloperba® is administered like cough syrup with a dosage of 0.6mg per 5ml, offering advantages for patients who struggle with pills. The liquid format enables more flexible dosing and titration options, particularly beneficial for gout patients with renal or hepatic impairment.

The Orphan Drug Designation applies to conditions affecting fewer than 200,000 individuals in the US. If approved, it would grant seven years of market exclusivity for treating pericarditis, an inflammatory condition of the heart's protective membrane.

Scilex Holding Company (NASDAQ: SCLX) has received approval from Health Canada for ELYXYB®, their ready-to-use oral solution for acute migraine treatment. ELYXYB® is the only FDA-approved oral solution in its category and demonstrates pain relief in as fast as 15 minutes, with significant relief compared to placebo within 45 minutes in approximately 50% of patients.

The Canadian market represents a significant opportunity, with over 2.7 million Canadians affected by migraines and the migraine therapeutics market projected to reach $400 million by 2025. The drug, which is manufactured in Canada, offers a first-line treatment option with potentially lower gastrointestinal side effects compared to other NSAIDs.